If a change can alter the finished device representation, patient exposure, contact profile, or chemistry story, the existing biological evaluation usually needs to be re-checked instead of assumed valid.
That does not always mean full retesting. It means running a structured reassessment so you can determine which parts of the existing evidence still hold and which parts need updating.
Material-change issues are often underestimated because the change-control description sounds minor. In reality, even a nominally small supplier, process, or formulation change can shift the chemical and biological safety profile enough that the old BEP or BER no longer cleanly represents the current device.
When Does a Material Change Require Biological Re-Evaluation?
ISO 10993 logic is straightforward on this point: if the change can affect biological safety, it needs evaluation. The practical challenge is recognizing when that threshold is crossed and documenting the answer in a way that holds up during internal review, notified body questions, or FDA scrutiny.
Changes That Commonly Trigger Re-Evaluation
- Raw material supplier change: nominally identical specifications can still hide differences in impurities, processing aids, or residuals.
- Formulation or additive change: colorants, fillers, plasticizers, stabilizers, or resin blends can materially affect the biological risk story.
- Sterilization change: switching between EO, gamma, e-beam, steam, or other methods can alter residues and final-device chemistry.
- Manufacturing or process change: cleaning, coating, surface treatment, assembly, or packaging changes may affect what reaches the patient.
- Indication or contact-profile expansion: a geometry or use change can push the device into a different contact type or duration category.
The Right Way to Think About Reassessment
The key question is not just "Did something change?" It is "Does the existing evidence still represent the changed device?" If the answer is uncertain, the biological evaluation needs a structured review rather than a shortcut statement that nothing important changed.
The Structured Re-Evaluation Process
- Step 1: document the change clearly. Define the old state, the new state, and why the change occurred.
- Step 2: reassess contact and endpoint logic. Confirm whether contact type, duration, or applicable endpoints have shifted.
- Step 3: compare evidence against the changed device. Review testing, literature, equivalence arguments, and chemistry data for continued relevance.
- Step 4: identify gaps. Determine whether chemistry, toxicology, literature, or targeted testing needs to be updated.
- Step 5: update the file. Revise the BEP, BER, risk-management cross-references, and submission narrative where needed.
Why Supplier Changes Are Often Missed
Supplier changes are one of the most common hidden triggers because teams often rely on matching material names or high-level specifications. But supplier-specific impurities, processing differences, or undocumented minor chemistry differences can still matter. That is why "same spec" is not always the end of the discussion.
When Retesting Is Not Automatically Required
Reassessment does not always mean new biological testing. In many cases, strong comparability logic, updated chemistry, targeted toxicology, or a revised endpoint rationale can close the gap more efficiently than running a broad new test program. The key is to make that decision consciously and document it well.
If the changed device would make you uneasy using the old evidence package without explanation, that is usually a sign the file needs a structured re-evaluation rather than a one-line change-control conclusion.
What a Good Output Looks Like
A good reassessment ends with a clear answer: what changed, what endpoints or assumptions are affected, what existing evidence remains valid, what additional support is needed, and what exact BEP, BER, or risk-file updates should now be made.
Need to decide whether a device change requires updated chemistry, toxicology, testing, or just a tighter rationale?
Discuss Your Project Back to Insights